Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism.
Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs.
Browser Use is an open-source Python library that enables AI agents to control web browsers, making it easy for LLMs to interact with any website through a clean, model-agnostic API.
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser automation frameworks like Playwright, providing a clean, model-agnostic interface that makes it straightforward for AI agents to navigate websites, fill forms, extract information, and complete multi-step web tasks without requiring developers to write custom browser control code.
Equator Therapeutics vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.